Core Viewpoint - Beijing Sunshine Nuohuo Pharmaceutical Research Co., Ltd. has applied for a one-month extension to respond to the merger and acquisition review inquiry letter received from the Shanghai Stock Exchange [1][2] Group 1: Company Announcement - The company plans to acquire 100% equity of Jiangsu Langyan Life Science Technology Holdings Co., Ltd. through the issuance of shares and convertible bonds, while also raising matching funds from no more than 35 specific investors [1] - The company received the inquiry letter from the Shanghai Stock Exchange on November 28, 2025, regarding the asset purchase and fundraising [1] - The company has initiated a thorough review of the inquiry letter with all parties involved in the transaction and intermediary institutions to ensure the response is accurate and complete [1] Group 2: Regulatory Approval - The transaction is subject to approval from the Shanghai Stock Exchange and requires registration consent from the China Securities Regulatory Commission before implementation [2] - There is uncertainty regarding whether the transaction will pass the review and obtain the necessary regulatory approvals [2]

证券代码：688621 证券简称：阳光诺和 公告编号：2025-112 公司收到《审核问询函》后，立即会同本次重组的交易各方及中介机构就《审 核问询函》中所涉及的问题认真研究并逐项落实。为确保回复内容的真实、准确、 完整，经与交易各方及中介机构审慎协商，公司已向上交所提交延期回复的书面 申请，延期时间不超过 1 个月，并在期限届满前披露《审核问询函》回复并提交 相关文件。 公司本次交易事项尚需经上交所审核，并获得中国证券监督管理委员会（以 下简称"中国证监会"）注册同意后方可实施，最终能否通过上交所审核，并获 得中国证监会同意注册的决定及其时间尚存在不确定性。公司将根据该事项的进 1 展情况，按照相关规定和要求及时履行信息披露义务，敬请广大投资者注意投资 风险。 特此公告。 北京阳光诺和药物研究股份有限公司董事会 北京阳光诺和药物研究股份有限公司 关于延期回复《关于北京阳光诺和药物研究股份有限 公司发行股份及可转换公司债券购买资产并募集配 套资金暨关联交易的审核问询函》的公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性依法承担法律责任。 ...

Group 1 - Jizhi Co., Ltd. plans to acquire at least 51% equity in Pumai Technology through cash payment, aiming to gain control over the company, which is a leading enterprise in the field of robot performance testing and calibration in China [1] - Yaxing Chemical's subsidiary intends to transfer 7.14% equity for 60 million yuan to another fund under the same control, indicating strategic investment movements within the same management group [2] - Weigao Bio's application for clinical trials of subcutaneous human immunoglobulin has been accepted by the National Medical Products Administration, targeting primary immunodeficiency diseases [3] Group 2 - Sentai Co., Ltd.'s controlling shareholder plans to increase shareholding by at least 100 million yuan within 12 months, aiming to enhance confidence in the company's future [4] - Health元's subsidiary has received acceptance for the marketing authorization application of Lecanemab injection, which is intended for moderate to severe plaque psoriasis patients [5][11] - Sunshine Nuohuo has signed a technical development contract for the STC008 injection project, with a total payment of 500 million yuan, indicating significant investment in cancer treatment [6] Group 3 - Hunan YN has been designated as a delivery warehouse for lithium carbonate by the Guangzhou Futures Exchange, enhancing its position in the lithium market [7] - Tianji Co., Ltd. is pushing for the industrialization of lithium sulfide material preparation, although it faces risks in commercialization [8] - Yuandong Bio has received FDA approval for Methylene Blue injection, expanding its product portfolio in the U.S. market [10] Group 4 - Nanshan Aluminum has established a wholly-owned subsidiary in Hainan with an investment of 5 million yuan, focusing on high-end aluminum products [13] - ST Xifa plans to acquire 50% equity in Lhasa Beer, aiming for full ownership, with the transaction currently in the planning stage [14] - Hengrui Medicine's SHR-A1904 injection has been included in the list of breakthrough therapy products, indicating its potential in treating advanced gastric cancer [12] Group 5 - Chengdu Gas is planning to merge three subsidiaries, streamlining operations and enhancing efficiency [26] - Baoli Electric intends to invest 50 million yuan to establish a wholly-owned subsidiary focused on key equipment and solutions in energy storage [27] - Huadian International has successfully put the second unit of its Longkou Phase IV project into commercial operation, marking a significant milestone in its energy production capacity [34]

北京阳光诺和药物研究股份有限公司 关于 STC008 注射液签署《技术开发合同》的公告 证券代码：688621 证券简称：阳光诺和 公告编号：2025-111 《技术开发合同》，现将具体情况公告如下： 一、合同审议程序情况 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性依法承担法律责任。 根据《上海证券交易所科创板股票上市规则》《北京阳光诺和药物研究股份 有限公司章程》等法律法规、规范性文件及公司管理制度的有关规定，本合同的 签署及生效无需提交公司董事会或公司股东会审议。公司已履行了签署本合同的 内部审批程序。 二、合同标的和对方当事人情况 重要内容提示: 目前 STC008 仍处于 I 期临床试验阶段，鉴于创新药具备高科技、高风险、 高附加值的特性，药品从临床试验开展至最终获批上市的周期长、环节多，全流 程易受多种不确定因素影响；新药上市后的销售表现亦受制于市场环境、行业发 展等多重变量。同时，本合同中所约定的里程碑付款需要满足一定的条件，最终 里程碑付款尚存在不确定性。敬请广大投资者谨慎决策，注意防范投资风险。 阳光诺和与星浩控股就共同 ...

Core Viewpoint - The company has entered into a collaboration agreement with Zhejiang Xinghao Holdings for the development of the STC008 injection project, which is currently in Phase I clinical trials [1] Group 1: Financial Aspects - The company will receive an initial payment of RMB 50 million and subsequent milestone payments totaling RMB 500 million (including tax) [1] - The company will also earn an 8% share of the net sales (excluding tax) from the project [1] Group 2: Project Details - STC008 is a self-initiated research project aimed at treating cancer cachexia in patients with advanced solid tumors [1] - The project is currently in the Phase I clinical trial stage, which is characterized by a long and complex approval process influenced by various uncertainties [1] Group 3: Market Considerations - The sales performance of the new drug post-launch will be affected by market conditions and industry developments [1] - The milestone payments outlined in the contract are contingent upon meeting certain conditions, introducing an element of uncertainty regarding their realization [1]

Group 1 - The core point of the article is that Yangguang Nuohuo (688621) has signed a cooperation agreement with Zhejiang Xinghao Holdings to jointly develop the STC008 injection project [1] - According to the technical development contract, the company will receive an initial payment of 50 million yuan and subsequent milestone payments, totaling 500 million yuan (including tax), along with an 8% sales share of the net sales (excluding tax) [1] - STC008 is a self-initiated research and development project by the company, primarily aimed at treating cancer cachexia in patients with advanced solid tumors, and is currently in the Phase I clinical trial stage [1]

Core Viewpoint - The company, Sunlight Nuohe (688621.SH), has signed a technology development contract with Zhejiang Xinghao Holding Partnership (Limited Partnership) to jointly develop the STC008 injection project, which is expected to positively impact the company's future performance and enhance profitability [1] Financial Summary - The company will receive an initial payment of 50 million yuan and subsequent milestone payments, totaling 500 million yuan (including tax), along with an 8% share of net sales [1] Project Status - The STC008 project is currently in Phase I clinical trials, indicating a long development cycle and multiple risks related to the research and market environment [1]

Core Viewpoint - The company has entered into a cooperation agreement with Zhejiang Xinghao Holdings to jointly develop the STC008 injection project, which is expected to positively impact future performance and enhance profitability [1] Group 1: Financial Terms - The company will receive an initial payment of RMB 50 million and subsequent milestone payments, totaling RMB 500 million (including tax) [1] - The company will also receive an 8% share of the net sales (excluding tax) from the project [1] Group 2: Project Details - STC008 is a self-initiated research and development project aimed at treating cancer cachexia in patients with advanced solid tumors [1] - The project is currently in the Phase I clinical trial stage [1]

Core Viewpoint - The company, Sunlight Nuohe (688621.SH), has entered into a cooperation agreement with Zhejiang Xinghao Holdings to jointly develop the STC008 injection project, which is expected to positively impact future performance and enhance profitability [1] Group 1: Agreement Details - The company will receive an initial payment of RMB 50 million and subsequent milestone payments, totaling RMB 500 million (including tax) [1] - The agreement includes an 8% sales share of the net sales (excluding tax) [1] Group 2: Project Information - STC008 is a self-initiated research and development project aimed at treating cancer cachexia in patients with advanced solid tumors [1] - The project is currently in the Phase I clinical trial stage [1]

Group 1 - The core viewpoint of the news highlights a significant increase in the Shanghai Stock Exchange's Sci-Tech Innovation Board Innovative Drug Index, with a rise of 3.26% as of December 19, 2025, driven by strong performances from constituent stocks such as Chengdu Xian Dao (up 10.44%) and Yifang Bio (up 9.82%) [1] - The recent announcement by the National Healthcare Security Administration and the Ministry of Human Resources and Social Security regarding the 2025 National Basic Medical Insurance Drug List includes 114 new drugs, of which 50 are innovative drugs, marking an 88% success rate, a 12 percentage point increase from 2024 [3] - The total R&D investment by innovative drug companies on the Sci-Tech Innovation Board reached a new high in the first three quarters of 2025, with a year-on-year increase of over 10% and an R&D intensity of 42%, significantly surpassing the overall level of A-shares [4] Group 2 - The collaboration between Innovent Biologics and Takeda Pharmaceutical regarding three innovative cancer drugs has been completed, with Innovent receiving a total upfront payment of $1.2 billion, including a strategic investment of $100 million, and potential milestone payments of up to $10.2 billion [5] - The CXO industry is entering a new high prosperity cycle, driven by external improvements, including overseas interest rate cuts and domestic recovery, with a focus on innovative drug companies benefiting from policy support and innovation upgrades [6] - The implementation of the "Medicare + Commercial Insurance" multi-layered medical security system is seen as a substantial breakthrough, with nearly 90% of new drugs approved by Sci-Tech Board biopharmaceutical companies included in the insurance list [3][4]